FETROJA Drug Patent Profile

When do Fetroja patents expire, and what generic alternatives are available?

Fetroja is a drug marketed by Shionogi Inc and is included in one NDA. There are three patents protecting this drug.

This drug has eighty-five patent family members in thirty-eight countries.

The generic ingredient in FETROJA is cefiderocol sulfate tosylate. One supplier is listed for this compound. Additional details are available on the cefiderocol sulfate tosylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Fetroja

Fetroja was eligible for patent challenges on November 14, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 3, 2035. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for FETROJA

International Patents:	85
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	5
Drug Prices:	Drug price information for FETROJA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FETROJA
What excipients (inactive ingredients) are in FETROJA?	FETROJA excipients list
DailyMed Link:	FETROJA at DailyMed

See drug prices for FETROJA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FETROJA

Constraining patent/regulatory exclusivity:

10,004,750

NDA:

209445

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FETROJA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rutgers Robert Wood Johnson Medical School	Phase 4
Assaf-Harofeh Medical Center	Phase 4
Rambam Health Care Campus	Phase 4

See all FETROJA clinical trials

Pharmacology for FETROJA

Drug Class

Cephalosporin Antibacterial

US Patents and Regulatory Information for FETROJA

FETROJA is protected by five US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 10,004,750.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shionogi Inc	FETROJA	cefiderocol sulfate tosylate	POWDER;INTRAVENOUS	209445-001	Nov 14, 2019		RX	Yes	Yes	9,238,657		Y	Y
Shionogi Inc	FETROJA	cefiderocol sulfate tosylate	POWDER;INTRAVENOUS	209445-001	Nov 14, 2019		RX	Yes	Yes
Shionogi Inc	FETROJA	cefiderocol sulfate tosylate	POWDER;INTRAVENOUS	209445-001	Nov 14, 2019		RX	Yes	Yes	10,004,750		Y	Y
Shionogi Inc	FETROJA	cefiderocol sulfate tosylate	POWDER;INTRAVENOUS	209445-001	Nov 14, 2019		RX	Yes	Yes

International Patents for FETROJA

When does loss-of-exclusivity occur for FETROJA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hungary

Japan

Lithuania

Malaysia

Mexico

Morocco

Philippines

Poland

Portugal

San Marino

Serbia

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering FETROJA around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1118536
South Africa	201102024	CEPHALOSPORIN HAVING CATECHOL GROUP
South Korea	20180088750
Chile	2011000939

Supplementary Protection Certificates for FETROJA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2960244	2020C/541	Belgium		PRODUCT NAME: CEFIDEROCOL, OPTIONEEL IN DE VORM VAN EEN FARMACEUTISCH ZOUT OF SOLVAAT; AUTHORISATION NUMBER AND DATE: EU/1/20/1434 20200424
2960244	CA 2020 00049	Denmark		PRODUCT NAME: CEFIDEROCOL, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT; REG. NO/DATE: EU/1/20/1434 20200424
2960244	C202030051	Spain		PRODUCT NAME: CEFIDEROCOL, OPCIONALMENTE EN FORMA DE UNA SAL O SOLVATO FARMACEUTICAMENTE ACEPTABLE.; NATIONAL AUTHORISATION NUMBER: EU/1/20/1434; DATE OF AUTHORISATION: 20200423; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1434; DATE OF FIRST AUTHORISATION IN EEA: 20200423
2960244	LUC00179	Luxembourg		PRODUCT NAME: CEFIDEROCOL, EVENTUELLEMENT SOUS LA FORME D'UN SEL OU D'UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/20/1434 20200424

Market Dynamics and Financial Trajectory for FETROJA (Fosfomycin Trometamol)

Last updated: July 27, 2025

Introduction

FETROJA (fosfomycin trometamol) has emerged as a significant player amid the global antimicrobial landscape, especially within the niche of uncomplicated urinary tract infections (UTIs). Developed by pharma giants such as Heron Therapeutics, FETROJA targets an evolving market driven by rising antimicrobial resistance, shifting regulatory policies, and increasing healthcare demand for effective outpatient treatments. This analysis explores the market dynamics influencing FETROJA’s financial trajectory, outlining factors impacting its growth, competitive positioning, and future opportunities.

Pharmacological Profile and Clinical Significance

FETROJA is an oral formulation of fosfomycin, a broad-spectrum bactericidal antibiotic. Approved by the FDA in 2018, FETROJA is primarily indicated for uncomplicated UTIs caused by susceptible bacteria, including E. coli and Enterococcus faecalis. Its mechanism involves inhibition of bacterial cell wall synthesis, rendering it effective against multidrug-resistant strains that threaten traditional antibiotics.

The antibiotic’s broad-spectrum activity, combined with its convenient dosing regimen—single-dose therapy—positions FETROJA as an advantageous alternative, fulfilling a critical unmet need amid escalating antimicrobial resistance (AMR).

Market Drivers

1. Rising Antimicrobial Resistance

AMR has become a global health crisis. The increased prevalence of multidrug-resistant (MDR) uropathogens diminishes the efficacy of conventional antibiotics. According to the CDC, over 2.8 million antibiotic-resistant infections occur annually in the U.S. alone, with approximately 35,000 deaths. FETROJA’s efficacy against resistant strains has made it a go-to option for clinicians, bolstering demand.

2. Unmet Medical Needs in UTIs

Urinary tract infections represent a substantial segment of bacterial infections worldwide, with an estimated 150 million cases annually. The convenience of single-dose oral therapy attracts both physicians and patients, especially for outpatient management, aligning with healthcare systems’ shift toward cost-effective, minimally invasive treatments.

3. Regulatory Landscape and Approvals

While approved in the U.S. by the FDA, regulatory stances in Europe and Asia are evolving. The European Medicines Agency (EMA) is reviewing fosfomycin-containing formulations, potentially expanding FETROJA’s commercial footprint. Such approvals can unlock additional markets, fueling revenue growth.

4. Competitive Environment

FETROJA faces competition from established broad-spectrum antibiotics like nitrofurantoin, trimethoprim-sulfamethoxazole, and fluoroquinolones. However, rising resistance to these agents positions FETROJA favorably, especially where resistance rates exceed clinical thresholds for other drugs.

5. Prescribing Patterns and Healthcare Adoption

Physicians’ increasing preference for antibiotics with proven efficacy against resistant organisms directly influences FETROJA’s use. Its favorable safety profile, low relapse rates, and outpatient administration further accelerate adoption.

Market Challenges

1. Limited Indications

Currently, FETROJA’s approved use is restricted to uncomplicated UTIs. Expanding indications to prostatitis, complicated UTIs, or systemic infections could significantly alter its financial trajectory but face regulatory and clinical hurdles.

2. Access and Reimbursement Policies

Pricing strategies, reimbursement policies, and formulary placements influence market penetration. As an innovative yet premium-priced medication, FETROJA’s commercial success is sensitive to healthcare payers’ acceptance.

3. Competition from New-Generation Antibiotics

Emerging antibiotics like gepotidacin and plazomicin, with unique mechanisms, may challenge fosfomycin’s market share, especially in resistant infections.

Financial Trajectory and Revenue Forecasts

1. Revenue Generation Post-Launch

Initial sales post-FDA approval in 2018 demonstrated moderate uptake, driven by targeted indications and limited awareness. In 2022, Heron Therapeutics reported estimates of approximately $50 million in global sales, with the U.S. accounting for over 80%. These figures reflect conservative adoption, primarily within hospital outpatient settings.

2. Growth Catalysts

Factors poised to enhance revenue include:

• Market Expansion: Pending approvals in Europe and Asia can multiply addressable markets by 2-3x.
• Expanded Indications: Regulatory approvals for complicated UTIs or intra-abdominal infections could access broader patient populations.
• Strategic Partnerships: Licensing agreements or co-marketing initiatives can accelerate dissemination.
• Increased Awareness & Education: Strategies targeting clinicians emphasize FETROJA’s role amid rising resistance, boosting prescriptions.

3. Short- and Medium-Term Outlook

Analysts project a compound annual growth rate (CAGR) of approximately 12-15% from 2023 to 2028. Revenue could potentially reach $150-200 million globally within this period, assuming successful market penetration, approval expansions, and sustained clinical demand.

4. Risks and Uncertainties

• Pricing Pressures: Payers may negotiate discounts or limit reimbursement.
• Regulatory Delays: Approval setbacks in major markets could hinder growth.
• Emerging Resistances: Bacterial evolution might reduce fosfomycin's efficacy over time.

Competitive Positioning and Strategic Implications

FETROJA’s unique position as an oral, single-dose antibiotic against resistant UTIs confers a competitive edge. To maximize profitability, Heron Therapeutics should focus on:

• Enhancing awareness of clinical efficacy.
• Securing approvals for broader indications.
• Establishing robust global distribution channels.
• Engaging in collaborations with healthcare providers and payers to optimize access.

Conclusion

FETROJA’s market dynamics are shaped by the global push against antimicrobial resistance, evolving regulatory landscapes, and shifting prescriber preferences. Its financial trajectory appears promising, conditional on successful market expansion, indication broadening, and sustained clinical demand. While challenges—such as reimbursement hurdles and competitive innovations—persist, FETROJA’s strategic positioning within the resistant UTI niche offers substantial growth potential.

---

Key Takeaways

• The global shift toward effective, resistance-appropriate antibiotics enhances FETROJA’s market prospects.
• Expanding approvals beyond the U.S. can significantly bolster revenue streams.
• Strategic advocacy, clinical education, and partnerships are vital for capturing market share.
• Competitive pressures from emerging antibiotics necessitate continuous innovation and clinical evidence.
• Financial growth depends heavily on regulatory success, payer acceptance, and expanding clinical indications.

---

FAQs

1. What are the primary factors driving FETROJA’s market growth?
Rising antimicrobial resistance, its efficacy against MDR pathogens, outpatient treatment convenience, and regulatory approvals are key drivers.

2. Are there significant barriers to FETROJA’s market expansion?
Yes. Barriers include limited current approved indications, reimbursement challenges, and competition from other antibiotics and emerging agents.

3. How does FETROJA compare to traditional antibiotics for UTIs?
FETROJA offers a single-dose oral regimen with proven efficacy against resistant strains, whereas traditional antibiotics may face resistance issues and require longer courses.

4. What markets are most promising for FETROJA’s future growth?
Europe and Asia represent promising markets pending regulatory approval; broader indications could further expand its reach.

5. What strategic moves should Heron Therapeutics consider to maximize FETROJA’s potential?
They should pursue indication expansion, strengthen global partnerships, engage clinicians through education, and advocate for supportive reimbursement policies.

---

Sources:

[1] CDC. Antibiotic Resistance Threats in the United States, 2019.
[2] FDA. FETROJA (fosfomycin trometamol) prescribing information, 2018.
[3] European Medicines Agency. Assessment Reports on Fosfomycin formulations.
[4] Heron Therapeutics. Annual Financial Reports, 2022.